Are BPC-157 and TB-500 still legal after the April 2026 reclassification?
The regulatory picture changed in 2026. US regulators removed several peptides, including BPC-157 and TB-500, from the Category 2 list that had restricted them. Important: being removed from that list is NOT the same as being approved. These peptides are still not approved for human use, cannot be bought without a prescription, and gray-market sales are not legal. Whether licensed compounding pharmacies may prepare them is still being decided. This is general information, not legal or medical advice - talk to a licensed physician about approved, evidence-based options.
- April 15, 2026 announcement: 12 peptides removed from Category 2, effective April 23, 2026
- Peptides affected: BPC-157, TB-500, Semax, Epitalon, Melanotan II, GHK-Cu (injectable), KPV, MOTS-C, LL-37, DiHexa, DSIP (Emideltide), PEG-MGF
- July 23-24, 2026 PCAC meeting reviews 503A Bulk Drug Substances List additions: BPC-157 (free base and acetate), KPV, TB-500, MOTs-C on July 23; Emideltide (DSIP), Semax, Epitalon on July 24
- Separate track: Melanotan II, GHK-Cu injectable, LL-37, PEG-MGF, DiHexa - review expected before February 2027
- Removal from Category 2 does NOT mean: peptides are approved for human use, can be purchased without a prescription, gray market sales are legal, or 503A pharmacies can automatically begin compounding them
Your guided peptide companion.
PRTCL walks beginners through their first peptide with confidence - guided reconstitution, syringe unit math from your own numbers, vial tracking, and answers to questions like this one. Built for first-timers, useful for everyone.
- · Guided walkthrough for your first dose
- · Your vial and your dose, converted into syringe units
- · Vial inventory and dose log tracking
- · A library where every claim cites its source
Free to start.